Prognostic survival model for people diagnosed with invasive cutaneous melanoma

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Baade, Peter D ^a,b,c   Royston, Patrick ^d   Youl, Philipa H ^a,b,c   Weinstock, Martin A ^e,f,g   Geller, Alan ^h   Aitken, Joanne F ^a,b,c  

^a CANCER COUNCIL QUEENSLAND   (Australia)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^c GRIFFITH UNIVERSITY   (Australia)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e PROVIDENCE VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f RHODE ISLAND HOSPITAL   (United States)

^g BROWN UNIVERSITY   (United States)

^h HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Melanoma; Population based; Prognostic model; Risk; Survival; Thickness

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER REGISTRY; CANCER SURVIVAL; CLINICAL FEATURE; CUTANEOUS MELANOMA; EXTERNAL VALIDITY; FEMALE; HUMAN; INTERNAL VALIDITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA SEVERITY INDEX; MIDDLE AGED; PREDICTION; SKIN DISEASE ASSESSMENT; SKIN ULCER; SKINFOLD THICKNESS; SURVIVAL TIME; TUMOR INVASION; TUMOR LOCALIZATION; VERY ELDERLY; HEALTH SURVEY; KAPLAN MEIER METHOD; MELANOMA; MORTALITY; PROGNOSIS; QUEENSLAND; REGISTER; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; MODELS, STATISTICAL; POPULATION SURVEILLANCE; PROGNOSIS; QUEENSLAND; REGISTRIES; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84924075996     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1024-4     Document Type: Article

References (41)

1. GLOBOCAN 2008, Cancer incidence and mortality worldwide: IARC CancerBase No. 10 [Internet] [http://globocan.iarc.fr/ ]
2. Green AC, Baade P, Coory M, Aitken JF, Smithers M. Population-based 20-year survival among people diagnosed with thin melanomas in Queensland, Australia. J Clin Oncol. 2012;30(13):1462-7.
3. Hu CY, Xing Y, Cormier JN, Chang GJ. Assessing the utility of cancer-registry-processed cause of death in calculating cancer-specific survival. Cancer. 2013;119(10):1900-7.
4. Eisemann N, Jansen L, Holleczek B, Waldmann A, Luttmann S, Emrich K, et al. Up-to-date results on survival of patients with melanoma in Germany. Br J Dermatol. 2012;167(3):606-12.
5. Jeffreys M, Sarfati D, Stevanovic V, Tobias M, Lewis C, Pearce N, et al. Socioeconomic inequalities in cancer survival in New Zealand: the role of extent of disease at diagnosis. Cancer Epidemiol Biomarkers Prev. 2009;18(3):915-21.
6. AIHW. Cancer survival and prevalence in Australia: period estimates from 1982 to 2010. Asia Pac J Clin Oncol. 2013;9(1):29-39.
7. Forsea AM, Del Marmol V, de Vries E, Bailey EE, Geller AC. Melanoma incidence and mortality in Europe: new estimates, persistent disparities. Br J Dermatol. 2012;167(5):1124-30.
8. Gimotty PA, Guerry D, Ming ME, Elenitsas R, Xu X, Czerniecki B, et al. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American joint committee on cancer staging. J Clin Oncol. 2004;22(18):3668-76.
9. Xing Y, Chang GJ, Hu CY, Askew RL, Ross MI, Gershenwald JE, et al. Conditional survival estimates improve over time for patients with advanced melanoma: results from a population-based analysis. Cancer. 2010;116(9):2234-41.
10. Steyerberg EW, Moons KG, van der Windt DA, Hayden JA, Perel P, Schroter S, et al. Prognosis research strategy (PROGRESS) 3: prognostic model research. PLoS Med. 2013;10(2):e1001381.
11. Balch CM, Gershenwald JE, Soong S-j, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199-206.
12. Balch CM, Soong S-J, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American joint committee on cancer melanoma staging system. J Clin Oncol. 2001;19(16):3622-34.
13. Soong SJ, Ding S, Coit D, Balch CM, Gershenwald JE, Thompson JF, et al. Predicting survival outcome of localized melanoma: an electronic prediction tool based on the AJCC Melanoma Database. Ann Surg Oncol. 2010;17(8):2006-14.
14. Egger ME, Dunki-Jacobs EM, Callender GG, Quillo AR, Scoggins CR, Martin 2nd RC, et al. Outcomes and prognostic factors in nodular melanomas. Surgery. 2012;152(4):652-9. discussion 659-660.
15. Coory M, Smithers M, Aitken J, Baade P, Ring I. Urban-rural differences in survival from cutaneous melanoma in Queensland. Aust N Z J Public Health. 2006;30(1):71-4.
16. Lyth J, Hansson J, Ingvar C, Mansson-Brahme E, Naredi P, Stierner U, et al. Prognostic subclassifications of T1 cutaneous melanomas based on ulceration, tumour thickness and Clark's level of invasion: results of a population-based study from the Swedish Melanoma Register. Br J Dermatol. 2013;168(4):779-86.
17. Lange JR, Palis BE, Chang DC, Soong SJ, Balch CM. Melanoma in children and teenagers: an analysis of patients from the National Cancer Data Base. J Clin Oncol. 2007;25(11):1363-8.
18. Grulich AE, Swerdlow AJ, Silva IDS, Beral V. Is the apparent rise in cancer mortality in the elderly real? analysis of changes in certification and coding of cause of death in England and Wales, 1970-1990. Int J Cancer. 1995;63(2):164-8.
19. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343-6.
20. Royston P, Lambert PC. Flexible parametric survival analysis using stata: beyond the cox model. College Station, Texas: Stata Press; 2011.
21. Royston P, Parmar MK. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med. 2002;21(15):2175-97.
22. Rubin D. Multiple imputation for nonresponse in surveys. New York: Wiley; 1987.
23. White I, Royston P, Wood A. Multiple imputation using chained equations: issues and guidance for practice. Stat Med. 2011;30(4):377-99.
24. Reid N. A conversation with Sir David Cox. Stat Sci. 1994;9(3):439-55.
25. Sauerbrei W, Royston P. Building multivariable prognostic and diagnostic models: transformation of the predictors by using fractional polynomials. J R Stat Soc (Series A). 1999;162:71-94.
26. Royston P, Sauerbrei W. Building multivariable regression models with continuous covariates in clinical epidemiology-with an emphasis on fractional polynomials. Methods Inf Med. 2005;44(4):561-71.
27. Royston P: A smooth covariate rank transformation for use in regression models with a sigmoid dose-response function. Submitted.
28. Royston P, Sauerbrei W. A new measure of prognostic separation in survival data. Stat Med. 2004;23(5):723-48.
29. Ambler G, Brady AR, Royston P. Simplifying a prognostic model: a simulation study based on clinical data. Stat Med. 2002;21(24):3803-22.
30. Royston P, Sauerbrei W. Multivariable model - building: a pragmatic approach to regression anaylsis based on fractional polynomials for modelling continuous variables. Hoboken: Wiley; 2008.
31. Royston P, Parmar MK, Sylvester R. Construction and validation of a prognostic model across several studies, with an application in superficial bladder cancer. Stat Med. 2004;23(6):907-26.
32. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Coit DG, Atkins MB, et al. Age as a prognostic factor in patients with localized melanoma and regional metastases. Ann Surg Oncol. 2013;20(12):3961-8.
33. Wisco OJ, Sober AJ. Prognostic factors for melanoma. Dermatol Clin. 2012;30(3):469-85.
34. Royston P, Parmar M, Altman DG: External validation and updating of a prognostic survival model (Research report No. 307). In.: Department of statistical science, University College London; 2010.
35. Andersson TM-L, Dickman P, Eloranta S, Lambe M, Lambert P: Estimating the loss in expectation of life due to cancer using flexible parametric survival models. Stat Med; In press.
36. Baade PD, Youlden DR, Chambers SK. When do I know I am cured? Using conditional estimates to provide better information about cancer survival prospects. Med J Aust. 2011;194(2):73-7.
37. Yu XQ, Baade PD, O'Connell DL. Conditional survival of cancer patients: an Australian perspective. BMC Cancer. 2012;12:460.
38. Hinchliffe SR, Lambert PC. Flexible parametric modelling of cause-specific hazards to estimate cumulative incidence functions. BMC Med Res Methodol. 2013;13:13.
39. Cramb SM, Garvey G, Valery PC, Williamson JD, Baade PD. The first year counts: cancer survival among Indigenous and non-Indigenous Queenslanders, 1997-2006. Med J Aust. 2012;196(4):270-4.
40. Colzani E, Liljegren A, Johansson AL, Adolfsson J, Hellborg H, Hall PF, et al. Prognosis of patients with breast cancer: causes of death and effects of time since diagnosis, age, and tumor characteristics. J Clin Oncol. 2011;29(30):4014-21.
41. Crowther MJ, Lambert PC. A general framework for parametric survival analysis. Stat Med. 2014;33(30):5280-97.